Search Results

You are looking at 61 - 70 of 151 items for :

  • "renal cell carcinoma" x
Clear All
Full access

Cell Carcinoma Metastases Taunk Neil K. a MD, MS Spratt Daniel E. a MD Bilsky Mark b MD Yamada Yoshiya a MD 6 2015 13 13 6 6 801 801 809 809 jnccn0130801 10.6004/jnccn.2015.0093 Follow-Up Management of Patients With

Full access

? Burstein Harold J. MD, PhD 6 2012 10 10 6 6 681 681 682 682 0100681 10.6004/jnccn.2012.0070 Ten Years of Progress in Renal Cell Carcinoma Jonasch Eric MD Motzer Robert J. MD 6 2012 10 10 6 6 690 690 693 693 0100690 10.6004/jnccn

Full access

.2019.7345 Conditional Survival of Patients With Nonmetastatic Renal Cell Carcinoma: How Cancer-Specific Mortality Changes After Nephrectomy Palumbo Carlotta a b MD Mistretta Francesco A. a c MD Knipper Sophie a d MD Pecoraro Angela a e MD Tian Zhe a PhD

Full access

Enrique Soto-Perez-de-Celis, Pedro N. Aguiar Jr, Mónica L. Cordón, Yanin Chavarri-Guerra and Gilberto de Lima Lopes Jr

extrapolated QoL data from previously published studies of cabozantinib in renal cell carcinoma (RCC). 14 The QoL utilities of patients taking placebo were obtained from the placebo arm of the RESORCE trial, which studied the use of regorafenib in a similar

Full access

Margaret MD 10 2015 13 13 10 10 1167 1167 1167 1167 0131167 10.6004/jnccn.2015.0144 The Right Drug for the Right Patient: Navigating Systemic Therapy Options in Metastatic Renal Cell Carcinoma and Future Directions Choueiri Toni K. MD Motzer

Full access

factor (VEGF) receptors. The VEGF pathway plays a distinct role in angiogenesis, which is critical in the growth and survival of solid tumors. Positive topline results from a phase III clinical study in advanced renal cell carcinoma have been reported

Full access

Saber Amin, Michael Baine, Jane Meza and Chi Lin

of HER2 inhibitors, epidermal growth factor receptor inhibitors, BRAF kinase inhibitors, and tyrosine kinase inhibitors in BMs from breast, non–small cell lung cancer (NSCLC), melanoma, and renal cell carcinoma and thus could be used in individual

Full access

Erica L. Mayer, Nancy U. Lin and Harold J. Burstein

Tomczak P . Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC) [abstract] . J Clin Oncol 2006 ; 24 ( suppl 1 ): Abstract LBA3

Full access

Justin Famoso, Gerald Lemole, Srinath Sundararajan and Baldassarre Stea

of current management strategies. Case Report A 75-year-old white woman with a past medical history of hypertension and hypercholesterolemia and a family history of male breast cancer in a paternal uncle and renal cell carcinoma in a son presented to

Full access

Laura J. Libby, Navneet Narula, Helen Fernandes, James F. Gruden, David J. Wolf and Daniel M. Libby

approved for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma (HCC), and thyroid carcinoma. 9 However, it was discontinued because of skin toxicity and lack of therapeutic effect (persistent chest pain, dyspnea, and hemoptysis